2021 Q4 Form 10-Q Financial Statement

#000161883521000240 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $3.570M $1.712M $278.0K
YoY Change 2000.0% 515.83%
Cost Of Revenue $1.755M $955.0K $317.0K
YoY Change 602.0% 201.26%
Gross Profit $1.815M $757.0K -$39.00K
YoY Change -2368.75% -2041.03%
Gross Profit Margin 50.84% 44.22% -14.03%
Selling, General & Admin $30.57M $35.43M $21.90M
YoY Change 2.19% 61.76% 153.65%
% of Gross Profit 1684.52% 4679.66%
Research & Development $8.659M $8.701M $4.217M
YoY Change 45.53% 106.33% -25.53%
% of Gross Profit 477.08% 1149.41%
Depreciation & Amortization $285.0K $268.0K $60.00K
YoY Change 137.5% 346.67% -14.29%
% of Gross Profit 15.7% 35.4%
Operating Expenses $39.23M $45.08M $26.43M
YoY Change 9.38% 70.54% 84.89%
Operating Profit -$37.42M -$43.37M -$26.16M
YoY Change 4.08% 65.81% 82.95%
Interest Expense -$12.92M -$29.50M -$3.080M
YoY Change 252.02% 857.86% -1566.67%
% of Operating Profit
Other Income/Expense, Net -$1.211M -$30.69M -$3.741M
YoY Change 13.18% 720.42% -849.7%
Pretax Income -$51.55M -$74.06M -$29.90M
YoY Change 26.97% 147.72% 116.68%
Income Tax $6.000K $0.00 $2.000K
% Of Pretax Income
Net Earnings -$51.55M -$74.06M -$29.90M
YoY Change 26.98% 147.7% 116.69%
Net Earnings / Revenue -1444.09% -4325.99% -10755.04%
Basic Earnings Per Share -$0.48 -$0.37
Diluted Earnings Per Share -$4.786M -$0.48 -$0.37
COMMON SHARES
Basic Shares Outstanding 163.1M shares 154.3M shares 81.21M shares
Diluted Shares Outstanding 154.3M shares 81.21M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.732M $14.86M $86.70M
YoY Change -84.19% -82.87% 142.18%
Cash & Equivalents $7.732M $14.86M $86.70M
Short-Term Investments $100.0K
Other Short-Term Assets $8.285M $25.92M $10.50M
YoY Change -79.49% 146.88% 600.0%
Inventory $7.915M $9.947M $3.164M
Prepaid Expenses
Receivables $6.449M $4.031M $1.243M
Other Receivables $0.00 $147.0K $500.0K
Total Short-Term Assets $30.14M $54.90M $102.1M
YoY Change -69.16% -46.22% 171.98%
LONG-TERM ASSETS
Property, Plant & Equipment $5.774M $5.769M $1.976M
YoY Change 33.23% 191.95% 261.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.203M $991.0K $1.074M
YoY Change 14.79% -7.73% 80.2%
Total Long-Term Assets $12.37M $12.52M $10.25M
YoY Change 1.09% 22.21% 603.36%
TOTAL ASSETS
Total Short-Term Assets $30.14M $54.90M $102.1M
Total Long-Term Assets $12.37M $12.52M $10.25M
Total Assets $42.51M $67.43M $112.3M
YoY Change -61.34% -39.97% 188.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.32M $6.788M $5.427M
YoY Change -3.05% 25.08% 5.11%
Accrued Expenses $8.370M $9.022M $4.607M
YoY Change 87.0% 95.83% -28.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $48.10M
YoY Change -100.0% -100.0%
Long-Term Debt Due $108.9M $68.72M
YoY Change
Total Short-Term Liabilities $137.7M $94.69M $65.69M
YoY Change 78.13% 44.14% 340.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $26.70M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $4.424M $4.871M $6.400M
YoY Change -27.48% -23.89%
Total Long-Term Liabilities $4.424M $31.57M $6.400M
YoY Change -85.87% 393.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $137.7M $94.69M $65.69M
Total Long-Term Liabilities $4.424M $31.57M $6.400M
Total Liabilities $142.1M $126.3M $72.12M
YoY Change 30.81% 75.07% 383.55%
SHAREHOLDERS EQUITY
Retained Earnings -$860.7M -$809.1M -$614.9M
YoY Change 31.3% 31.58% 22.86%
Common Stock $751.3M $745.2M $655.1M
YoY Change 14.38% 13.76% 24.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$104.3M -$58.83M $40.21M
YoY Change
Total Liabilities & Shareholders Equity $42.51M $67.43M $112.3M
YoY Change -61.34% -39.97% 188.1%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$51.55M -$74.06M -$29.90M
YoY Change 26.98% 147.7% 116.69%
Depreciation, Depletion And Amortization $285.0K $268.0K $60.00K
YoY Change 137.5% 346.67% -14.29%
Cash From Operating Activities -$21.27M -$37.37M -$35.82M
YoY Change -45.59% 4.32% 148.4%
INVESTING ACTIVITIES
Capital Expenditures -$53.00K -$597.0K -$830.0K
YoY Change -96.27% -28.07% 4050.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $530.0K
YoY Change -100.0% -114.25%
Cash From Investing Activities -$53.00K -$597.0K -$300.0K
YoY Change -96.27% 99.0% -91.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.866M 16.00K -600.0K
YoY Change -60.41% -102.67% 42.86%
NET CHANGE
Cash From Operating Activities -21.27M -37.37M -35.82M
Cash From Investing Activities -53.00K -597.0K -300.0K
Cash From Financing Activities 9.866M 16.00K -600.0K
Net Change In Cash -11.45M -37.95M -36.72M
YoY Change -26.5% 3.34% 97.63%
FREE CASH FLOW
Cash From Operating Activities -$21.27M -$37.37M -$35.82M
Capital Expenditures -$53.00K -$597.0K -$830.0K
Free Cash Flow -$21.21M -$36.77M -$34.99M
YoY Change -43.67% 5.09% 142.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001618835
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020Q2 evfm Class Of Warrant Or Right Vesting Term
ClassOfWarrantOrRightVestingTerm
P5Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Local Phone Number
LocalPhoneNumber
550-1900
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36754
dei Entity Registrant Name
EntityRegistrantName
EVOFEM BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8527075
dei Entity Address Address Line1
EntityAddressAddressLine1
12400 High Bluff Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
163144964 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14856000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48892000 USD
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
9384000 USD
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
22559000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4031000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1067000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
9947000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
7162000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16685000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18050000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
54903000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
97730000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5769000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4334000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5764000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6856000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
991000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1048000 USD
CY2021Q3 us-gaap Assets
Assets
67427000 USD
CY2020Q4 us-gaap Assets
Assets
109968000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6788000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10641000 USD
CY2021Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
68724000 USD
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
52409000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9022000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4476000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5253000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6514000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2418000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2290000 USD
CY2021Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
26696000 USD
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
25211000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2482000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
953000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
94687000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
77283000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4774000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6030000 USD
CY2021Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
97000 USD
CY2020Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
97000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
126254000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
108621000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
5000000 shares
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
5000000 shares
CY2021Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
155208456 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
155208456 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81351533 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81351533 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
16000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
745194000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
656827000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5089000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-809126000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-655488000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-58827000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1347000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67427000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109968000 USD
CY2021Q3 us-gaap Revenues
Revenues
1712000 USD
CY2020Q3 us-gaap Revenues
Revenues
278000 USD
CY2020Q3 us-gaap Revenues
Revenues
278000 USD
us-gaap Revenues
Revenues
4674000 USD
us-gaap Revenues
Revenues
278000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
955000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
317000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
317000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2300000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
317000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8701000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4217000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4217000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24470000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11104000 USD
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
30468000 USD
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14700000 USD
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14700000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
88230000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
32553000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4957000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7200000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7200000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19057000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24077000 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
45081000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
26434000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
26434000 USD
us-gaap Operating Expenses
OperatingExpenses
134057000 USD
us-gaap Operating Expenses
OperatingExpenses
68051000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43369000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26156000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26156000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-129383000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-67773000 USD
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
21000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
21000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
14000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
152000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1190000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-657000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-657000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3521000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1010000 USD
CY2021Q3 evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
0 USD
CY2020Q3 evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
0 USD
evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
0 USD
evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
64049000 USD
CY2021Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-29505000 USD
CY2020Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-3105000 USD
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-20737000 USD
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
30971000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30692000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3741000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3741000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24244000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33936000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74061000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29897000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29897000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-153627000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101709000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-74061000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-29899000 USD
us-gaap Net Income Loss
NetIncomeLoss
-153638000 USD
us-gaap Net Income Loss
NetIncomeLoss
-101711000 USD
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.63
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154265434 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154265434 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81206101 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81206101 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120691057 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120691057 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62434949 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62434949 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-74061000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-29899000 USD
us-gaap Net Income Loss
NetIncomeLoss
-153638000 USD
us-gaap Net Income Loss
NetIncomeLoss
-101711000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
5089000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
0 USD
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
5089000 USD
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
0 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68972000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29899000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-148549000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101711000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1347000 USD
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
7000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3464000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-46151000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-13638000 USD
CY2021Q2 evfm Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options
StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions
196000 USD
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
300000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2993000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-33426000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
8964000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
5089000 USD
CY2021Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
20000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1091000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-74061000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-58827000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15636000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
73000 USD
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
25000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3401000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19146000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
1021000 USD
CY2020Q2 evfm Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options
StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions
177000 USD
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2777000 USD
CY2020Q2 evfm Short Swing Profit Disgorgement
ShortSwingProfitDisgorgement
187000 USD
CY2020Q2 evfm Adjustments To Additional Paid In Capital Reclassification Of Warrants And Purchase Rights Liability
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsAndPurchaseRightsLiability
11015000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6034000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-52666000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
68539000 USD
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
67000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1637000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-29899000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
40210000 USD
us-gaap Net Income Loss
NetIncomeLoss
-153638000 USD
us-gaap Net Income Loss
NetIncomeLoss
-101711000 USD
evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
0 USD
evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
64049000 USD
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-20737000 USD
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
30971000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7548000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11072000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
738000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
181000 USD
us-gaap Lease Cost
LeaseCost
1035000 USD
us-gaap Lease Cost
LeaseCost
542000 USD
us-gaap Interest Expense
InterestExpense
2152000 USD
us-gaap Interest Expense
InterestExpense
992000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2964000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1243000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1908000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2912000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
196000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
337000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2636000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
833000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7650000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
81534000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
103738000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
159000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2000 USD
evfm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 USD
evfm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3781000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-486000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9070000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3252000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-505000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5996000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2900000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1261000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1283000 USD
evfm Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1071000 USD
evfm Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
357000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-125402000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65750000 USD
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
250000 USD
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
250000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
8233000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2886000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000 USD
evfm Proceeds From Short Swing Profit Disgorgement
ProceedsFromShortSwingProfitDisgorgement
0 USD
evfm Proceeds From Short Swing Profit Disgorgement
ProceedsFromShortSwingProfitDisgorgement
187000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
735000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
867000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
327000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2869000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80827000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129309000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47211000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
71209000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72251000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16625000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25040000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87834000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7618000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
714000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
73000 USD
evfm Reclassification Of Warrants And Purchase Rights To Equity
ReclassificationOfWarrantsAndPurchaseRightsToEquity
0 USD
evfm Reclassification Of Warrants And Purchase Rights To Equity
ReclassificationOfWarrantsAndPurchaseRightsToEquity
11015000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14856000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86697000 USD
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
9384000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ignificant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items, the trade accounts receivable credit loss reserve estimate, the discount rate used in estimating the fair value of the lease right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use assets and lease liabilities, the assumptions used in estimating the fair value of convertible notes, warrants and purchase rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, the assumptions used in estimating the fair value of stock-based compensation expense and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards (performance-based RSAs). These assumptions are more fully described in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3- Revenue</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5- Convertible Notes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7- Fair Value of Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8- Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ic9d2cd75ed5a460d8b9504826c567c06_67" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 11- Stock-based Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held.</span></div>The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses.
CY2020Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
25000000 USD
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
103700000 USD
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
14900000 USD
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
81500000 USD
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
9000000 USD
CY2021Q3 evfm Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
-39800000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-809100000 USD
CY2021Q3 evfm Product Revenue Variable Consideration Liability Current
ProductRevenueVariableConsiderationLiabilityCurrent
2500000 USD
CY2020Q2 evfm Securities Sold Under Purchase Agreement
SecuritiesSoldUnderPurchaseAgreement
15000000 USD
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
337000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25040000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87834000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
79686738 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
79686738 shares
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19532661 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19532661 shares
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
498000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
332000 USD
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2095000 USD
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4162000 USD
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7354000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2668000 USD
CY2021Q3 us-gaap Inventory Gross
InventoryGross
9947000 USD
CY2020Q4 us-gaap Inventory Gross
InventoryGross
7162000 USD
CY2020Q2 evfm Securities Sold Under Purchase Agreement
SecuritiesSoldUnderPurchaseAgreement
10000000 USD
CY2020Q2 evfm Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement
PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement
10000000 USD
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.44
CY2020Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
58100000 USD
CY2020Q2 evfm Purchase Agreement Threshold Amount Of Aggregate Gross Proceeds From Future Sale Of Equity Securities
PurchaseAgreementThresholdAmountOfAggregateGrossProceedsFromFutureSaleOfEquitySecurities
100000000 USD
CY2020Q2 evfm Class Of Warrant Or Right Liability
ClassOfWarrantOrRightLiability
46700000 USD
CY2020Q2 evfm Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
64000000 USD
CY2020Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
34100000 USD
CY2020Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
34100000 USD
CY2020Q2 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
34100000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
15800000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
11000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
5100000 USD
CY2021Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
-29500000 USD
CY2021Q3 evfm Debt Instrument Restrictive Covenants Cumulative Net Sales Requirement
DebtInstrumentRestrictiveCovenantsCumulativeNetSalesRequirement
100000000 USD
CY2021Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
68700000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1889000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16685000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18050000 USD
CY2016Q3 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
1900000 USD
CY2016Q3 us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
600000 USD
CY2016Q3 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
1300000 USD
CY2016Q3 evfm Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate
DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate
0.050
CY2016Q3 evfm Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment
DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment
300000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7658000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5485000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1151000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5769000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4334000 USD
CY2021Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
200000 USD
CY2020Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
100000 USD
us-gaap Depreciation Nonproduction
DepreciationNonproduction
700000 USD
us-gaap Depreciation Nonproduction
DepreciationNonproduction
200000 USD
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
800000 USD
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
800000 USD
CY2021Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
136000 USD
CY2020Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
214000 USD
CY2021Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
55000 USD
CY2020Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
34000 USD
CY2021Q3 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
991000 USD
CY2020Q4 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
1048000 USD
CY2021Q3 evfm Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
5577000 USD
CY2020Q4 evfm Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
1417000 USD
CY2021Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2320000 USD
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
22746000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
614000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
366000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9022000 USD
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
564000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
301000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1631000 USD
CY2021Q3 evfm Accrued Manufacturing Related Costs Current
AccruedManufacturingRelatedCostsCurrent
210000 USD
CY2020Q4 evfm Accrued Manufacturing Related Costs Current
AccruedManufacturingRelatedCostsCurrent
498000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4476000 USD
CY2021Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
68724000 USD
CY2021Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
68724000 USD
CY2021Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
68724000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
70233000 USD
CY2020Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
50752000 USD
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
50752000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
2300000 USD
CY2021Q3 us-gaap Paid In Kind Interest
PaidInKindInterest
2300000 USD
CY2020Q2 evfm Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement
PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement
10000000 USD
evfm Lessee Operating Lease Number Of Vehicles Leased
LesseeOperatingLeaseNumberOfVehiclesLeased
72 vehicle
CY2019Q4 evfm Office Square Footage
OfficeSquareFootage
24474 sqft
CY2019Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q2 evfm Office Square Footage
OfficeSquareFootage
8816 sqft
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
649000 USD
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
583000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
466000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
1760000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
998000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M14D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y5M4D
CY2021Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.12
CY2020Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.12
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2480000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2163000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2192000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1502000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8986000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1794000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7192000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1779000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
552000 USD
CY2021Q3 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0 claim
CY2020Q4 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0 claim
CY2019Q2 evfm Compensation Agreement Potential Bonus As A Percent Of Consulting Fees Earned
CompensationAgreementPotentialBonusAsAPercentOfConsultingFeesEarned
1
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
67767107 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.54
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
67767107 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 evfm Common Stock Reserved Upon Exercise Of Common Stock Warrants
CommonStockReservedUponExerciseOfCommonStockWarrants
67767107 shares
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
83069895 shares
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1091000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1637000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7548000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11072000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
70000 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
631200 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3126525 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2873685 shares

Files In Submission

Name View Source Status
0001618835-21-000240-index-headers.html Edgar Link pending
0001618835-21-000240-index.html Edgar Link pending
0001618835-21-000240.txt Edgar Link pending
0001618835-21-000240-xbrl.zip Edgar Link pending
barransseparationagreement.htm Edgar Link pending
evfm-20210930.htm Edgar Link pending
evfm-20210930.xsd Edgar Link pending
evfm-20210930_cal.xml Edgar Link unprocessable
evfm-20210930_def.xml Edgar Link unprocessable
evfm-20210930_htm.xml Edgar Link completed
evfm-20210930_lab.xml Edgar Link unprocessable
evfm-20210930_pre.xml Edgar Link unprocessable
evfm-9302021xex311.htm Edgar Link pending
evfm-9302021xex312.htm Edgar Link pending
evfm-9302021xex321.htm Edgar Link pending
evofembiosciencesinc-de.htm Edgar Link pending
evofembiosciencesinc-de001.jpg Edgar Link pending
evofembiosciencesinc-de002.jpg Edgar Link pending
evofembiosciencesinc-de003.jpg Edgar Link pending
evofembiosciencesinc-de004.jpg Edgar Link pending
evofembiosciencesinc-de005.jpg Edgar Link pending
evofembiosciencesinc-de006.jpg Edgar Link pending
evofembiosciencesinc-de007.jpg Edgar Link pending
evofembiosciencesinc-de008.jpg Edgar Link pending
evofembiosciencesinc-de009.jpg Edgar Link pending
evofembiosciencesinc-de010.jpg Edgar Link pending
evofembiosciencesinc-de011.jpg Edgar Link pending
evofembiosciencesinc-de012.jpg Edgar Link pending
evofembiosciencesinc-de013.jpg Edgar Link pending
evofembiosciencesinc-de014.jpg Edgar Link pending
evofembiosciencesinc-de015.jpg Edgar Link pending
evofembiosciencesinc-de016.jpg Edgar Link pending
evofembiosciencesinc-de017.jpg Edgar Link pending
evofembiosciencesinc-de018.jpg Edgar Link pending
evofembiosciencesinc-de019.jpg Edgar Link pending
evofembiosciencesinc-de020.jpg Edgar Link pending
evofembiosciencesinc-de021.jpg Edgar Link pending
evofembiosciencesinc-de022.jpg Edgar Link pending
evofembiosciencesinc-de023.jpg Edgar Link pending
evofembiosciencesinc-de024.jpg Edgar Link pending
evofembiosciencesinc-de025.jpg Edgar Link pending
evofembiosciencesinc-de026.jpg Edgar Link pending
evofembiosciencesinc-de027.jpg Edgar Link pending
evofembiosciencesinc-de028.jpg Edgar Link pending
evofembiosciencesinc-de029.jpg Edgar Link pending
evofembiosciencesinc-de030.jpg Edgar Link pending
evofembiosciencesinc-de031.jpg Edgar Link pending
evofembiosciencesinc-de032.jpg Edgar Link pending
evofembiosciencesinc-de033.jpg Edgar Link pending
evofembiosciencesinc-de034.jpg Edgar Link pending
evofembiosciencesinc-de035.jpg Edgar Link pending
evofembiosciencesinc-de036.jpg Edgar Link pending
evofembiosciencesinc-de037.jpg Edgar Link pending
evofembiosciencesinc-de038.jpg Edgar Link pending
evofembiosciencesinc-de039.jpg Edgar Link pending
evofembiosciencesinc-de040.jpg Edgar Link pending
evofembiosciencesinc-de041.jpg Edgar Link pending
evofembiosciencesinc-de042.jpg Edgar Link pending
evofembiosciencesinc-de043.jpg Edgar Link pending
evofembiosciencesinc-de044.jpg Edgar Link pending
evofembiosciencesinc-de045.jpg Edgar Link pending
evofembiosciencesinc-de046.jpg Edgar Link pending
evofembiosciencesinc-de047.jpg Edgar Link pending
evofembiosciencesinc-de048.jpg Edgar Link pending
evofembiosciencesinc-de049.jpg Edgar Link pending
evofembiosciencesinc-de050.jpg Edgar Link pending
evofembiosciencesinc-de051.jpg Edgar Link pending
evofembiosciencesinc-de052.jpg Edgar Link pending
evofembiosciencesinc-de053.jpg Edgar Link pending
evofembiosciencesinc-de054.jpg Edgar Link pending
evofembiosciencesinc-de055.jpg Edgar Link pending
evofembiosciencesinc-de056.jpg Edgar Link pending
evofembiosciencesinc-de057.jpg Edgar Link pending
evofembiosciencesinc-de058.jpg Edgar Link pending
evofembiosciencesinc-de059.jpg Edgar Link pending
evofembiosciencesinc-de060.jpg Edgar Link pending
evofembiosciencesinc-de061.jpg Edgar Link pending
evofembiosciencesinc-de062.jpg Edgar Link pending
evofembiosciencesinc-de063.jpg Edgar Link pending
evofembiosciencesinc-de064.jpg Edgar Link pending
evofembiosciencesinc-de065.jpg Edgar Link pending
evofembiosciencesinc-de066.jpg Edgar Link pending
evofembiosciencesinc-de067.jpg Edgar Link pending
evofembiosciencesinc-de068.jpg Edgar Link pending
evofembiosciencesinc-de069.jpg Edgar Link pending
evofembiosciencesinc-de070.jpg Edgar Link pending
evofembiosciencesinc-de071.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending